^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KANK1 (KN Motif And Ankyrin Repeat Domains 1)

    i
    Other names: KANK1, KN Motif And Ankyrin Repeat Domains 1, KANK, KIAA0172, ANKRD15, KN Motif And Ankyrin Repeat Domain-Containing Protein 1, Ankyrin Repeat Domain-Containing Protein 15, Kidney Ankyrin Repeat-Containing Protein, Ankyrin Repeat Domain 15, CPSQ2
    2ms
    Dramatic Response to Entrectinib in a Rare Glioneuronal Tumor Harboring an NTRK2 Fusion. (PubMed, Oncologist)
    This case highlights the essential role of DNA methylation profiling in resolving diagnostic ambiguity and guiding targeted treatment in CNS tumors. It further supports the potential efficacy of entrectinib in NTRK fusion-positive glioneuronal tumors.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ATRX (ATRX Chromatin Remodeler) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    Rozlytrek (entrectinib)
    7ms
    Sertoli cell tumor associated with ovarian sex cord tumor with annular tubules in a patient with 46 XY disorder of sex development and 9p24.3 deletion, case report. (PubMed, J Obstet Gynaecol Res)
    Hormonal replacement therapy was not initiated due to the potential risk of tumor recurrence, and follow-up imaging was scheduled every 6 months for the first 2 years and then annually. No recurrence was observed at 24 months.
    Journal
    |
    KANK1 (KN Motif And Ankyrin Repeat Domains 1) • DMRT1 (Doublesex And Mab-3 Related Transcription Factor 1)
    9ms
    Beyond Hybrid Morphology: A Large Series of Fusion-Driven Benign Peripheral Nerve Sheath Tumors Including 5 Tumors with Novel Fusions. (PubMed, Mod Pathol)
    Lastly, one tumor with a novel SRF::MYOCD fusion displayed morphologic features reminiscent of desmoplastic melanoma while exhibiting a combined neural and smooth muscle phenotype. Our data expands on the morphologic and molecular spectrum of fusion-driven hybrid peripheral nerve sheath tumors, including 5 previously undescribed fusions, and further expands on non-CNS schwannomas with VGLL3 fusions.
    Journal
    |
    KANK1 (KN Motif And Ankyrin Repeat Domains 1) • CDK5RAP2 (CDK5 Regulatory Subunit Associated Protein 2) • NCOA2 (Nuclear Receptor Coactivator 2) • RREB1 (Ras Responsive Element Binding Protein 1) • TEAD1 (TEA Domain Transcription Factor 1) • VGLL3 (Vestigial Like Family Member 3)
    9ms
    RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting. (PubMed, Front Genet)
    Most NTRK fusions were mutually exclusive from other genomic driver alterations, however, almost a third of tumor specimens (29%) contained at least one co-occurring genomic driver, which may affect treatment decisions. The high prevalence of oncogenic and likely oncogenic NTRK fusions detected in our analysis suggests that RNA hybrid-capture-based sequencing for fusion detection is a highly sensitive method for identifying clinically meaningful known and novel NTRK fusions, which may be missed with other detection methods, directly impacting therapeutic options and patient outcomes.
    Journal • Real-world evidence • Next-generation sequencing • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • TPM3 (Tropomyosin 3) • LMNA (Lamin A/C) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    10ms
    Identification of KANK1 as a tumor suppressor gene in pancreatic ductal adenocarcinoma. (PubMed, Biochem Biophys Res Commun)
    Functional assays demonstrated that KANK1 knockdown promotes pancreatic cancer cell proliferation and migration, along with activation of ERK signaling. Collectively, our findings establish KANK1 as a tumor suppressor in PDAC, whose loss facilitates tumor progression and presents a potential therapeutic target for pancreatic cancer treatment.
    Journal
    |
    KANK1 (KN Motif And Ankyrin Repeat Domains 1)
    1year
    Circle-seq reveals that eccDNA may be a key blood biomarker for HBV-associated liver cancer. (PubMed, Front Genet)
    Difference analysis showed that some eccDNAs had consistent and overlapping expressions with mRNAs. We found that LAMA4 [circle112550019-112550510] and KANK1 [circle674459-674907] are target genes related to HCC, and both of them may become potential biomarkers for the diagnosis and prognosis of HCC.
    Journal
    |
    KANK1 (KN Motif And Ankyrin Repeat Domains 1)
    1year
    A prospective study of methylated ctDNA in patients undergoing treatment for liver metastases from colorectal cancer. (PubMed, Eur J Surg Oncol)
    Preoperative meth-ctDNA may serve as an important biomarker to inform the multidisciplinary assessment and treatment planning of CRLM. Negative meth-ctDNA may indicate the optimal timing for liver intervention, whereas positive meth-ctDNA may indicate initiation or re-orientation of chemotherapy, or immediate local intervention. Our results confirm postoperative negative meth-ctDNA as a strong prognostic marker of survival.
    Journal
    |
    KANK1 (KN Motif And Ankyrin Repeat Domains 1)
    1year
    KANK1 promotes breast cancer development by compromising Scribble-mediated Hippo activation. (PubMed, Nat Commun)
    When these cells lose the contact with the BM and disassemble integrin adhesions, KANK1 is found at cell-cell junctions where it competes with the polarity and tumor suppressor Scribble for NOS1AP binding, which curbs the ability of Scribble to promote Hippo pathway activity. The consequences are stabilization and nuclear accumulation of TAZ, growth and survival of tumor cells and elevated breast cancer development.
    Journal
    |
    KANK1 (KN Motif And Ankyrin Repeat Domains 1)
    over1year
    ALK rearranged Spitz melanocytoma: a clinicopathological and molecular genetic analysis of two cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    ALK-rearranged Spitz melanocytoma represents a morphologically and genetically distinct subset of Spitz melanocytoma, characterized clinically by predilection in children and adolescents, with Spitzoid morphology in plexiform pattern, positive immunohistochemical stains, and rearrangement of ALK. As some cases show atypical features and high mitotic activity, a distinction from Spitz melanoma is warranted.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TPM3 (Tropomyosin 3) • SOX10 (SRY-Box 10) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • MITF (Melanocyte Inducing Transcription Factor)
    over1year
    NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors. (PubMed, Acta Neuropathol Commun)
    Four patients received adjuvant TRK inhibitor therapy (larotrectinib, repotrectinib, or entrectinib), among which three also received chemotherapy (n = 2) or proton therapy (n = 1). This patient had previously experienced relapse after the initial surgery and underwent autologous peripheral blood stem cell therapy with carboplatin/thiotepa and proton therapy. Conclusions Our study clarifies the distinct differences in the pathology and TRK inhibitor response between LGG and HGG with NTRK fusions.
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • MDM4 (The mouse double minute 4) • TPM3 (Tropomyosin 3) • TFG (Trafficking From ER To Golgi Regulator) • FKBP15 (FKBP Prolyl Isomerase 15) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • NTRK (Neurotrophic receptor tyrosine kinase) • SPECC1L (Sperm Antigen With Calponin Homology And Coiled-Coil Domains 1 Like) • GKAP1 (G Kinase Anchoring Protein 1) • KIF5A (Kinesin Family Member 5A)
    |
    carboplatin • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib) • thiotepa
    over1year
    Spitz Melanoma With SLC20A1::ALK Fusion: A Novel Fusion Previously Undescribed in Spitz Melanocytic Neoplasm. (PubMed, Am J Dermatopathol)
    Here, we present a case of Spitz melanoma harboring SLC20A1::ALK fusion, highlighting a novel fusion transcript not previously reported in Spitz melanocytic neoplasms, including Spitz melanomas. In addition, the tumor exhibits multiple aberrant chromosomal alterations characteristic of melanoma, along with a somatic mutation in GRM3.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TPM3 (Tropomyosin 3) • DCTN1 (Dynactin Subunit 1) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • MLPH (Melanophilin)
    over1year
    Potential involvement of KANK1 haploinsufficiency in centrosome aberrations. (PubMed, Biochim Biophys Acta Gen Subj)
    When EGR1 protein expression was reduced by siRNA technology, the number of cells exhibiting centrosomal amplification increased, along with the reduction of KANK1 protein expression, suggesting their functional relationship. Thus, KANK1 haploinsufficiency may contribute to centrosome aberrations through the network of haploinsufficiency-related genes.
    Journal
    |
    RHOA (Ras homolog family member A) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • EGR1 (Early Growth Response 1)